PABLO LUIS
ORTIZ ROMERO

Catedrático de universidad

Foto de PABLO LUIS

Foto de Claude Bernard University Lyon 1

Claude Bernard University Lyon 1

Villeurbanne, Francia

Publicaciones en colaboración con investigadores/as de Claude Bernard University Lyon 1 (4)

2022

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma
Dermatologic Therapy

2021

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data
Blood Advances, Vol. 5, pp. 5098-5106

2018

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet, Vol. 390, Núm. 10094, pp. 555-566